The trial will enrol male patients with metastatic castrate-resistant prostate cancer who have responded to prior lutetium 177 (¹⁷⁷Lu)-PSMA therapy. Credit: Peakstock/ Shutterstock.

Blue Earth Therapeutics has entered a clinical research partnership with University College London in the UK to progress the clinical development of an Alpha-labelled Radioligand Therapy (RLT) for prostate cancer.

This partnership focuses on executing a Phase I/II clinical trial aimed at assessing the safety, tolerability, and efficacy of ²²⁵Ac-rhPSMA-10.1 in male patients with advanced prostate cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial will enrol male patients with metastatic castrate-resistant prostate cancer who have responded to prior lutetium 177 (¹⁷⁷Lu)-PSMA therapy.

To be conducted at the UCL Cancer Institute by the Treatment Resistance Group, the trial will be led by professor Gerhardt Attard.

²²⁵Ac-rhPSMA-10.1 is said to be the second investigational compound in Blue Earth Therapeutics’ pipeline.

See Also:

It uses radiohybrid PSMA technology, enabling the creation of radiopharmaceutical therapeutics that can be labelled with beta- or alpha-emitting isotopes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During development, the pharmacokinetic profile of rhPSMA-10.1 was optimised to enhance the retention of radioactivity in tumour cells while minimising exposure to normal tissues.

The combination of these properties with longer-lived isotopes, such as ²²⁵Ac, could potentially deliver significantly higher doses of radiation directly to cancer cells.

Blue Earth is also conducting a trial of rhPSMA-10.1 labelled with the beta-emitting ¹⁷⁷Lu.

The company is now expanding its research by labelling the compound with the alpha-emitting isotope ²²⁵Ac.

Blue Earth Therapeutics CEO David Gauden said: “Our goal at Blue Earth Therapeutics is to deliver precise, targeted therapy specific to a patient’s condition.

“This collaboration aims to rapidly translate alpha-labelled rhPSMA-10.1 from the laboratory to the clinic, with the hope of helping patients who have advanced prostate cancer. We are delighted to collaborate with an illustrious academic institution such as UCL which is regularly ranked in the top ten academic institutions globally, and look forward to working with Professor Attard and his group on this important UK clinical research initiative.”